Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is poised to experience significant growth with their promising gene therapy, SGT-003, which has shown lower risk of side effects and potential to become a best-in-class treatment for DMD. The company also has other promising programs for rare diseases, such as Friedreich's ataxia and catecholaminergic polymorphic ventricular tachycardia, highlighting a high unmet need and potential for revenue and market opportunities. With a strong financial update and projected net loss, Solid Biosciences is well-positioned for future success in the life sciences industry.

Bears say

Solid Biosciences is a platform-enabled therapeutics company with a concentrated focus on gene therapy treatments for a variety of neuromuscular and cardiac diseases. The current outlook is negative as the company has not yet achieved any significant clinical or commercial success and faces competition and regulatory risks. Additionally, while the potential for positive outcomes in upcoming data readouts exists, there is also a significant potential for adverse events and setbacks in the clinical development process. With a current valuation that may not fully reflect these risks, the potential for a significant increase in stock price is limited.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.